<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>My Biopharma News Feed</title><link>http://yourdomain-or-some-place.com/custom_feed.xml</link><description>Daily curated &amp; AI-summarized biopharma news.</description><atom:link href="http://yourdomain-or-some-place.com/custom_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Fri, 07 Mar 2025 00:47:03 +0000</lastBuildDate><item><title>Trump administration policies could create headwinds across healthcare: Fitch</title><link>https://www.biopharmadive.com/news/trump-administration-policies-create-headwinds-healthcare-fitch-ratings/741615/</link><description>**Summary:**  
Fitch Ratings warns the current administration's policies could downgrade credit ratings for numerous companies, including major pharmaceutical firms. The agency highlights potential financial risks across sectors as regulatory changes threaten corporate stability.</description><pubDate>Tue, 04 Mar 2025 16:00:00 -0500</pubDate></item><item><title>Jazz expands in oncology with $935M deal for Chimerix</title><link>https://www.biopharmadive.com/news/jazz-chimerix-acquisition-cancer-drug-dordaviprone/741636/</link><description>Chimerix anticipates an FDA decision on accelerated approval for its innovative drug targeting a rare brain cancer, glioma, signaling potential breakthrough treatment for patients. The outcome could expedite access to the therapy, marking a pivotal moment for both glioma sufferers and the company's trajectory in oncology.</description><pubDate>Wed, 05 Mar 2025 11:53:00 -0500</pubDate></item><item><title>Tris to ask for approval of dual-acting pain drug</title><link>https://www.biopharmadive.com/news/tris-pain-drug-data-fda-approval-filing-plans/741727/</link><description>&lt;figure&gt;&lt;div&gt;&lt;img src="https://imgproxy.divecdn.com/OS1c9EP39nx8Jm_yJeMLUMuMcGmIQ_1qVwH6qxr5A6E/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg5NTQzMTM4LmpwZw==.webp" /&gt;&lt;/div&gt;&lt;/figure&gt;&lt;p&gt;Positive data from a pa...</description><pubDate>Thu, 06 Mar 2025 09:30:00 -0500</pubDate></item><item><title>Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy</title><link>https://www.biopharmadive.com/news/amgen-maritide-trials-duchenne-base-editing-wegovy-discount/741651/</link><description>&lt;figure&gt;&lt;div&gt;&lt;img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDgzOTIxNzkzLmpwZw==.webp" /&gt;&lt;/div&gt;&lt;/figure&gt;&lt;p&gt;Phase ...</description><pubDate>Thu, 06 Mar 2025 10:06:00 -0500</pubDate></item><item><title>Federal judge extends block on Trump plan to limit NIH payouts</title><link>https://www.biopharmadive.com/news/biotech-nih-funding-indirect-costs-trump-preliminary-injunction/741733/</link><description>**Summary:** A federal judge issued a nationwide preliminary injunction blocking the Biden administration’s plan to cap indirect costs for NIH grants, halting a policy with major implications for the U.S. pharmaceutical industry. The ruling pauses limits on funds covering administrative and facility expenses tied to medical research projects until the court completes its full legal review.</description><pubDate>Thu, 06 Mar 2025 11:16:00 -0500</pubDate></item><item><title>Makary, under review to run FDA, evades pressure to reinstate canceled vaccine meeting</title><link>https://www.biopharmadive.com/news/makary-senate-hearing-fda-vaccines-meeting/741765/</link><description>&lt;figure&gt;&lt;div&gt;&lt;img src="https://imgproxy.divecdn.com/PQrOy7-EaLMBudW-4Eke1hxKiYfDbJRxYFVqkZTf2Ns/g:nowe:0:104/c:1024:578/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjAzNjI1NTU5XzEuanBn.webp" /&gt;&lt;/div&gt;&lt;/figure&gt;&lt;p&gt;Ques...</description><pubDate>Thu, 06 Mar 2025 12:30:00 -0500</pubDate></item><item><title>Following FDA cuts, Trump nominee Makary vows ‘independent’ staff review</title><link>https://www.biopharmadive.com/news/makary-hearing-fda-staffing-review-layoffs/741807/</link><description>**Summary:** A Johns Hopkins surgeon emphasized the agency's significant expansion, pointing to its accelerated growth trajectory. He vowed that essential staff would receive "all the resources they need to do their job well," ensuring robust support amid the agency's development.</description><pubDate>Thu, 06 Mar 2025 15:42:00 -0500</pubDate></item><item><title>Vertex’s new pain drug gets first coverage nod from major insurer</title><link>https://www.biopharmadive.com/news/vertex-journavx-optum-united-health-coverage-tier-3/741850/</link><description>**Summary:**  
Optum, a UnitedHealth Group-owned pharmacy benefit manager, has temporarily added the drug Journavx to select commercial formularies as an interim measure while conducting a formal review. The provisional placement ensures patient access to the medication pending the completion of Optum’s comprehensive evaluation.</description><pubDate>Thu, 06 Mar 2025 17:59:00 -0500</pubDate></item><item><title>Transforming Early Detection in Oncology and Rare Diseases Using AI</title><link>https://www.fiercebiotech.com/premium/webinar/1368565</link><description>**Summary:**  
Join experts Chris Tackaberry and Dr. Will Ricketts in an exclusive webinar exploring how AI transforms early detection in oncology and rare diseases by unlocking insights from unstructured healthcare data. Discover real-world applications, including improved diagnosis and care coordination, backed by published outcomes in ASCO and Nature, to address the global challenge of delivering high-quality care amid resource constraints.  

*(The summary highlights the webinar’s focus on AI solutions, key challenges, and credible outcomes while maintaining engagement and accuracy.)*</description><pubDate>Mon, 24 Feb 2025 14:53:21 +0000</pubDate></item><item><title>The Oncology Market: 2025 Outlook</title><link>https://www.fiercebiotech.com/resource/oncology-market-2025-outlook</link><description>&lt;span class="field field--name-title field--type-string field--label-hidden"&gt;The Oncology Market: 2025 Outlook&lt;/span&gt;

            &lt;div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__ite...</description><pubDate>Tue, 25 Feb 2025 14:49:58 +0000</pubDate></item><item><title>Redefining vaccine trial recruitment</title><link>https://www.fiercebiotech.com/resource/redefining-vaccine-trial-recruitment</link><description>Clinical trials are essential for vaccine development, yet effective recruitment of diverse participants remains a key challenge. Avacare’s new white paper reveals data-driven strategies to streamline recruitment, enhance diversity, and improve trial efficiency—discover actionable insights for more inclusive and impactful research.  
*(Note: The second sentence balances promotional engagement with accuracy, directing readers to the resource while emphasizing the article’s focus on innovation and equity.)*</description><pubDate>Wed, 26 Feb 2025 14:26:35 +0000</pubDate></item><item><title>Using Client Centricity as Fuel for Innovative Biologics Development and Manufacturing Solutions</title><link>https://www.fiercebiotech.com/resource/using-client-centricity-fuel-innovative-biologics-development-and-manufacturing-solutions</link><description>**Engaged Summary:** Rentschler Biopharma’s whitepaper offers actionable strategies for biopharma professionals to tailor and optimize biologics development and manufacturing processes while maintaining high-quality standards, emphasizing client-centric solutions. Designed for scientists, manufacturing leads, and executives, it merges innovation with practical insights to streamline complex workflows and drive efficiency in an evolving industry.  

**Key Alignment:** Highlights the focus (client-centricity), audience relevance, and core purpose (quality + innovation) while crediting the source and ensuring brevity for a news feed.</description><pubDate>Tue, 04 Mar 2025 16:39:29 +0000</pubDate></item></channel></rss>
